DK2059525T3 - Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse - Google Patents

Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse

Info

Publication number
DK2059525T3
DK2059525T3 DK07786022.9T DK07786022T DK2059525T3 DK 2059525 T3 DK2059525 T3 DK 2059525T3 DK 07786022 T DK07786022 T DK 07786022T DK 2059525 T3 DK2059525 T3 DK 2059525T3
Authority
DK
Denmark
Prior art keywords
domain
split
presentation
preparing
methods
Prior art date
Application number
DK07786022.9T
Other languages
English (en)
Inventor
Michael Nassal
Claudia Skamel
Andreas Walker
Original Assignee
Universitaetsklinikum Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg filed Critical Universitaetsklinikum Freiburg
Application granted granted Critical
Publication of DK2059525T3 publication Critical patent/DK2059525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK07786022.9T 2006-09-08 2007-07-12 Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse DK2059525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06018847A EP1897887A1 (de) 2006-09-08 2006-09-08 Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung
PCT/EP2007/006190 WO2008028535A1 (de) 2006-09-08 2007-07-12 Split-core-partikel für die präsentation von fremdmolekülen, insbesondere für impfstoffartwendungen und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
DK2059525T3 true DK2059525T3 (da) 2012-03-05

Family

ID=37672012

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07786022.9T DK2059525T3 (da) 2006-09-08 2007-07-12 Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse

Country Status (22)

Country Link
US (1) US8282932B2 (da)
EP (2) EP1897887A1 (da)
JP (1) JP5160545B2 (da)
KR (1) KR20090059118A (da)
CN (1) CN101541828B (da)
AT (1) ATE538134T1 (da)
AU (1) AU2007294249B2 (da)
BR (1) BRPI0716545A2 (da)
CA (1) CA2662707C (da)
CO (1) CO6160336A2 (da)
CY (1) CY1112309T1 (da)
DK (1) DK2059525T3 (da)
ES (1) ES2377742T3 (da)
MX (1) MX2009002590A (da)
MY (1) MY146926A (da)
NZ (1) NZ575360A (da)
PL (1) PL2059525T3 (da)
PT (1) PT2059525E (da)
RU (1) RU2454462C2 (da)
SI (1) SI2059525T1 (da)
WO (1) WO2008028535A1 (da)
ZA (1) ZA200901825B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2528940T1 (sl) * 2010-01-25 2014-07-31 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
CN102464721B (zh) * 2010-11-17 2015-05-20 中国科学院上海巴斯德研究所 针对人肠道病毒71型的重组广谱性疫苗
WO2015133613A1 (ja) * 2014-03-07 2015-09-11 雅史 溝上 Ｂ型肝炎ウイルスレポーターベクター、ｂ型肝炎ウイルス様粒子及びそれを用いたｂ型肝炎治療薬のスクリーニング方法
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
US11535651B2 (en) 2017-08-02 2022-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis B nanoparticle-based vaccine for influenza virus
CN108048480B (zh) * 2017-11-24 2021-04-23 湖北大学 一种split-TEV-Fast系统的构建方法及其在检测蛋白相互作用中的应用
CA3107770C (en) 2018-08-16 2023-09-05 Emd Millipore Corporation Closed bioprocessing device
AU2021313111A1 (en) * 2020-07-24 2023-03-23 CR Therapeutics Co., Ltd. EBV-targeted allogeneic B cell vaccine and preparation method therefor
EP4373839A4 (en) * 2021-07-20 2025-12-17 Univ Johns Hopkins SUPRAMOLECULAR POLYMERS WITH HIGH AFFINITY FOR BINDING-RESULTED ANTIBODY PRECIPITATION AND CLEANSING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine

Also Published As

Publication number Publication date
EP1897887A1 (de) 2008-03-12
MX2009002590A (es) 2009-08-24
EP2059525B1 (de) 2011-12-21
CN101541828A (zh) 2009-09-23
PL2059525T3 (pl) 2012-04-30
CA2662707C (en) 2016-06-21
ZA200901825B (en) 2010-03-31
KR20090059118A (ko) 2009-06-10
US20100040646A1 (en) 2010-02-18
AU2007294249B2 (en) 2011-10-20
EP2059525A1 (de) 2009-05-20
CY1112309T1 (el) 2015-12-09
CA2662707A1 (en) 2008-03-13
JP5160545B2 (ja) 2013-03-13
CN101541828B (zh) 2013-09-04
US8282932B2 (en) 2012-10-09
CO6160336A2 (es) 2010-05-20
NZ575360A (en) 2010-11-26
PT2059525E (pt) 2012-02-27
JP2010502658A (ja) 2010-01-28
BRPI0716545A2 (pt) 2013-04-02
SI2059525T1 (sl) 2012-03-30
MY146926A (en) 2012-10-15
RU2009112721A (ru) 2010-10-20
ES2377742T3 (es) 2012-03-30
ATE538134T1 (de) 2012-01-15
WO2008028535A1 (de) 2008-03-13
RU2454462C2 (ru) 2012-06-27
AU2007294249A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ZA200901825B (en) Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
SG162687A1 (en) Caustic stable chromatography ligands
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
EP2987806A3 (en) Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
EA201270775A1 (ru) Связывающие сывороточный альбумин молекулы
MX389073B (es) Método para producir una proteína de fusión de anticuerpo.
UY31123A1 (es) Proteinas de fusion natriureticas
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
GB201008682D0 (en) Epitope tag for affinity based applications
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2011034622A3 (en) Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
WO2007130535A3 (en) Novel protein fusion/tag technology
WO2012028523A3 (en) Prokaryotic expression construct
ATE527345T1 (de) Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
ZA201808214B (en) Production of a horseradish peroxidase-igg fusion protein
ATE483810T1 (de) Entkopplung von dna-propagierung und proteinexpression für phagen-display
DK1963361T3 (da) Multimere komplekser af antigener og c4bp